Acute phase response and mineral status following low dose intravenous zoledronic acid in children

Bone

Volumn 41, Issue 3, 2007, Pages 366-370

  Munns, Craig F ^a,b   Rajab, Mansoor H ^a   Hong, Janet ^a   Briody, Julie ^a   Högler, Wolfgang ^a   McQuade, Mary ^a   Little, David G ^a,b   Cowell, Christopher T ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Children; Flu like symptoms; Hypocalcaemia; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADOLESCENT; ADULT; ARTICLE; AVASCULAR NECROSIS; BODY MASS; BODY SURFACE; BONE DISEASE; CHI SQUARE TEST; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DISTRACTION OSTEOGENESIS; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FISHER EXACT TEST; FLU LIKE SYNDROME; FREQUENCY ANALYSIS; HUMAN; HYPOCALCEMIA; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; NAUSEA; OSTEOPOROSIS; PAIN; PARESTHESIA; RANK SUM TEST; SEIZURE; SYMPTOMATOLOGY; VOMITING;

ACUTE-PHASE REACTION; ADOLESCENT; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; C-REACTIVE PROTEIN; CALCIUM; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOCALCEMIA; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; PARATHYROID HORMONE; PHOSPHATES;

EID: 34547605714     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.05.002     Document Type: Article

References (15)

1. Astrom E., and Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch. Dis. Child. 86 (2002) 356-364
2. Berenson J.R. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10 (2005) 52-62
3. Berenson J.R., Rosen L.S., Howell A., Porter L., Coleman R.E., Morley W., et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91 (2001) 1191-1200
4. Body J.J., Lortholary A., Romieu G., Vigneron A.M., and Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J. Bone Miner. Res. 14 (1999) 1557-1561
5. Breen T.L., and Shane E. Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. J. Clin. Oncol. 22 (2004) 1531-1532
6. Dicuonzo G., Vincenzi B., Santini D., Avvisati G., Rocci L., Battistoni F., et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J. Interferon Cytokine Res. 23 (2003) 649-654
7. Fleisch H. Bisphosphonates in Bone Disease, From the Laboratory to the Patient (2000), Academic Press, San Diego
8. Hogler W., Yap F., Little D., Ambler G., McQuade M., and Cowell C.T. Short-term safety assessment in the use of intravenous zoledronic acid in children. J. Pediatr. 145 (2004) 701-704
9. Munns C., Zacharin M.R., Rodda C.P., Batch J.A., Morley R., Cranswick N.E., et al. Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement. Med. J. Aust. 185 (2006) 268-272
10. Munns C.F., Rauch F., Travers R., and Glorieux F.H. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J. Bone Miner. Res. 20 (2005) 1235-1243
11. Nguyen H.V., Ingram K.B., and Beilin J. Profound hypocalcaemia after zoledronic acid treatment. Med. J. Aust. 182 (2005) 494-495
12. Peter R., Mishra V., and Fraser W.D. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ 328 (2004) 335-336
13. Rauch F., and Glorieux F.H. Osteogenesis imperfecta. Lancet 363 (2004) 1377-1385
14. Rauch F., Plotkin H., Travers R., Zeitlin L., and Glorieux F.H. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J. Clin. Endocrinol. Metab. 88 (2003) 986-992
15. Robinson R.E., Nahata M.C., Hayes J.R., Batisky D.L., Bates C.M., and Mahan J.D. Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy 24 (2004) 195-197